SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Vivimed Labs acquires Hungary based CDMO business Soneas

The acquisition brings clinical research and small scale commercial manufacturing abilities to Vivimed Labs.

Vivimed Labs has announced that its Spanish subsidiary Vivimed Labs Spain S.L has acquired Budapest (Hungary) based contract development and manufacturing organization (CDMO) Soneas. This acquisition was executed by Uquifa S.A, Vivimed Labs Spain’s subsidiary by acquiring stakes from two Hungarian companies, Lochlomond and Euroventures.

Uquifa is in the API business and has three USFDA compliant manufacturing sites in Spain and Mexico. It caters to the Generic API and CDMO API segments of the global pharmaceutical market.

The acquired company, Soneas focusses on the Innovator Pharmaceutical and Fine Chemical sectors and in 2017 reported revenues of €12.2mn. It brings pilot plant and over 180KL of key starting material (KSM) capacities to the Uquifa portfolio. This acquisition broadens Uquifa’s market offering in the CDMO space to undertake preclinical, phase I-III NCE project development as well as it also brings CMO opportunities to the company.

Uquifa believes the acquisition of Soneas will help it expand the CDMO business (40% of Uquifa sales). Uquifa is already present in USA, Europe and Japan.

Make sure your Financial Advisors worth their fees here we’re letting you know us more who we actually so click here to TRADE UP >> Bonaz Capital